2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10847BR
    SB-277011 hydrochloride (Standard) 215804-67-4
    SB-277011 hydrochloride (Standard) is the analytical standard of SB-277011 (hydrochloride) (HY-10847B). This product is intended for research and analytical applications. SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor (D3R) antagonist with Ki values of 10.7 nM and 11.2 nM at rodent and human D3R, respectively. SB-277011 hydrochloride displays 80- to 100-fold selectivity over other dopamine receptors with pKis of 8.0, 6.0, <5.2, and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively.
    SB-277011 hydrochloride (Standard)
  • HY-108497R
    L-803087 (Standard) 217480-26-7
    L-803087 (Standard) is the analytical standard of L-803087 (HY-108497). This product is intended for research and analytical applications. L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.
    L-803087 (Standard)
  • HY-108504R
    Co 102862 (Standard) 181144-66-1
    Co 102862 (Standard) is the analytical standard of Co 102862 (HY-108504). This product is intended for research and analytical applications. Co 102862 (V 102862) is a potent, broad-spectrum, state-dependent Na+ channel blocker. Co 102862 is also an orally active anticonvulsant.
    Co 102862 (Standard)
  • HY-108505R
    QX-314 chloride (Standard) 5369-03-9
    QX-314 chloride (Standard) is the analytical standard of QX-314 (chloride) (HY-108505). This product is intended for research and analytical applications. QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
    QX-314 chloride (Standard)
  • HY-108506S
    Licarbazepine-d3 1189917-36-9 98%
    Licarbazepine-d3 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine-d3
  • HY-108509R
    BMY-14802 hydrochloride (Standard) 105565-55-7
    BMY-14802 hydrochloride (Standard) is the analytical standard of BMY-14802 (hydrochloride) (HY-108509). This product is intended for research and analytical applications. BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects.
    BMY-14802 hydrochloride (Standard)
  • HY-108510R
    Rimcazole dihydrochloride (Standard) 75859-03-9
    Rimcazole dihydrochloride (Standard) is the analytical standard of Rimcazole (dihydrochloride) (HY-108510). This product is intended for research and analytical applications. Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer.
    Rimcazole dihydrochloride (Standard)
  • HY-108519R
    AS1892802 (Standard) 928320-12-1
    AS1892802 (Standard) is the analytical standard of AS1892802 (HY-108519). This product is intended for research and analytical applications. AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain.
    AS1892802 (Standard)
  • HY-108577R
    XE991 dihydrochloride (Standard) 122955-13-9 98%
    XE991 dihydrochloride (Standard) is the analytical standard of XE991 dihydrochloride. This product is intended for research and analytical applications. XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively.
    XE991 dihydrochloride (Standard)
  • HY-108584R
    Flindokalner (Standard) 187523-35-9 98%
    Flindokalner (Standard) is the analytical standard of Flindokalner. This product is intended for research and analytical applications. Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo.
    Flindokalner (Standard)
  • HY-108586R
    NS3623 (Standard) 343630-41-1
    NS3623 (Standard) is the analytical standard of NS3623 (HY-108586). This product is intended for research and analytical applications. NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels.
    NS3623 (Standard)
  • HY-108590R
    DMP-543 (Standard) 160588-45-4
    DMP-543 (Standard) is the analytical standard of DMP-543 (HY-108590). This product is intended for research and analytical applications. DMP-543 (XR-543) is a KV7 channel blocker, also acts as a potent neurotransmitter release enhancer.
    DMP-543 (Standard)
  • HY-108592R
    UCL 2077 (Standard) 918311-87-2
    UCL 2077 (Standard) is the analytical standard of UCL 2077 (HY-108592). This product is intended for research and analytical applications. UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels.
    UCL 2077 (Standard)
  • HY-108613R
    JJKK 048 (Standard) 1515855-97-6
    JJKK 048 (Standard) is the analytical standard of JJKK 048 (HY-108613). This product is intended for research and analytical applications. JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain.
    JJKK 048 (Standard)
  • HY-108615R
    CP-316819 (Standard) 186392-43-8 98%
    CP-316819 (GPi 819) Standard is the analytical standard of CP-316819 (HY-108615). This product is intended for research and analytical applications. CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.
    CP-316819 (Standard)
  • HY-108621R
    RS-25344 hydrochloride (Standard) 152815-28-6
    RS-25344 hydrochloride (Standard) is the analytical standard of RS-25344 (hydrochloride) (HY-108621). This product is intended for research and analytical applications. RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects.
    RS-25344 hydrochloride (Standard)
  • HY-108625R
    SHA 68 (Standard) 847553-89-3
    SHA 68 (Standard) is the analytical standard of SHA 68. This product is intended for research and analytical applications. SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn107 and NPSR Ile107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia.
    SHA 68 (Standard)
  • HY-108666R
    ATPγS tetralithium salt (Standard) 93839-89-5
    ATPγS tetralithium salt (Standard) is the analytical standard of ATPγS (tetralithium salt) (HY-108666). This product is intended for research and analytical applications. ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis.
    ATPγS tetralithium salt (Standard)
  • HY-108669R
    AZ10606120 dihydrochloride (Standard) 607378-18-7
    AZ10606120 dihydrochloride (Standard) is the analytical standard of AZ10606120 (dihydrochloride) (HY-108669). This product is intended for research and analytical applications. AZ10606120 dihydrochloride is a selective, high affinity antagonist for P2X7 receptor (P2X7R) at human and rat with an IC50 of about 10 nM. AZ10606120 dihydrochloride is little or no effect at other P2XR subtypes. AZ10606120 dihydrochloride has anti-depressant effects and reduces tumour growth.
    AZ10606120 dihydrochloride (Standard)
  • HY-108681R
    680C91 (Standard) 163239-22-3
    680C91 (Standard) is the analytical standard of 680C91 (HY-108681). This product is intended for research and analytical applications. 680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease.
    680C91 (Standard)
Cat. No. Product Name / Synonyms Application Reactivity